Dyne Therapeutics Past Earnings Performance

Past criteria checks 0/6

Dyne Therapeutics's earnings have been declining at an average annual rate of -42.9%, while the Biotechs industry saw earnings growing at 12.3% annually.

Key information

-42.9%

Earnings growth rate

23.9%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-53.8%
Net Margin	n/a
Last Earnings Update	31 Mar 2024

Recent past performance updates

No updates

Recent updates

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

Jan 11

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Jan 08

Revenue & Expenses Breakdown
Beta

How Dyne Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:DYN Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	-257	48	218
31 Dec 23	-236	31	211
30 Sep 23	-208	30	185
30 Jun 23	-189	30	165
31 Mar 23	-177	29	152
31 Dec 22	-168	28	143
30 Sep 22	-181	31	152
30 Jun 22	-182	30	154
31 Mar 22	-160	30	131
31 Dec 21	-149	29	121
30 Sep 21	-126	26	101
30 Jun 21	-97	23	74
31 Mar 21	-77	18	58
31 Dec 20	-59	13	45
30 Sep 20	-36	8	27
30 Jun 20	-28	5	21
31 Mar 20	-21	4	15
31 Dec 19	-15	3	11

Quality Earnings: DYN is currently unprofitable.

Growing Profit Margin: DYN is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DYN is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.

Accelerating Growth: Unable to compare DYN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DYN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: DYN has a negative Return on Equity (-53.84%), as it is currently unprofitable.

Dyne Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics, Inc. Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Dyne Therapeutics Presents New Preclinical Data from Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

Dyne Therapeutics, Inc. Announces New Preclinical Data from Its Myotonic Dystrophy Type 1 Program Will Be Featured in Presentations During the American Society of Gene & Cell Therapy

Dyne Therapeutics, Inc. Appoints Wildon Farwell as Chief Medical Officer

New 90-day low: US$17.71

Dyne Therapeutics Appoints Ashish Dugar as Senior Vice President, Global Head of Medical Affairs

New 90-day low: US$18.40

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $168 million.

Dyne Therapeutics, Inc. Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

New 90-day high: US$27.13

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Dyne Therapeutics, Inc. has filed an IPO in the amount of $100 million.

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Revenue & Expenses Breakdown
Beta